showed signs of inhibition of breast cancer tumour growth in BABL/c mice. In a later study, Chen et al. improved the potency of the SMU127 by modifying the ring system, while keeping all other structural features. One of the modified compounds -SMU-C13 possessed the highest TLR2 activity. Also, the in silico simulation indicated a tight fit into the known binding site.